We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

STX Shield Therapeutics Plc

0.35 (17.07%)
23 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.35 17.07% 2.40 23,775,141 16:40:28
Bid Price Offer Price High Price Low Price Open Price
2.30 2.40 2.40 2.05 2.05
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.45 18.22M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:40:28 O 1,500,000 2.20 GBX

Shield Therapeutics (STX) Latest News

Shield Therapeutics (STX) Discussions and Chat

Shield Therapeutics Forums and Chat

Date Time Title Posts
23/5/202418:23Shield Therapeutics: poised for a US licensing deal13,859
02/5/202408:14Shield Therapeutics 4,114
22/2/202408:59Shield therapeutics what next?1,974
22/2/202408:37Shield Therapeutics: Poised for a US deal1
12/4/202310:06Shorted to 10p454

Add a New Thread

Shield Therapeutics (STX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Shield Therapeutics (STX) Top Chat Posts

Top Posts
Posted at 22/5/2024 14:49 by qipincha
the share price was around 12p sep last year. This is significantly undervalued.

As the share price is recovering, It is expected it will soon go back to 3p 6p and 12p. Whether it can go beyond and when is depending on how quickly the company can sell enough volume to make a profit
Posted at 17/5/2024 19:50 by r9505571
Shield TherapeuticsSTXShare Price 7 Day 1 Year0.02 21.3% -73.2% Consensus revenue estimates fall by 34%The consensus outlook for revenues in fiscal year 2024 has deteriorated.2024 revenue forecast decreased from US$45.6m to US$30.3m.Forecast losses increased from -US$0.026 to -US$0.027 per share.Pharmaceuticals industry in the United Kingdom expected to see average net income growth of 34% next year.Consensus price target up from UK£0.02 to UK£0.16.Share price rose 21% to UK£0.018 over the past week.
Posted at 26/4/2024 11:04 by washingmachine
I’ve scrolled right back on the thread
You were Uber bullish like everyone else on here , the share price at the time was over 6 pence
Only two names were fighting against the tide
at the time
Who were both lambasted and ridiculed by the thread
Wally and Amaretto
Scroll back , very sobering.
R/W L at Price today
Posted at 25/4/2024 11:09 by ih_676530
The share price is heavily oversold on the tech chart,especially after today's drop. This should draw in value and chart traders. If Tuesday's results are as good as February's trading update then the share price could easily double in value in a single day.
Posted at 25/4/2024 08:00 by r9505571
Consensus revenue estimates fall by 19%The consensus outlook for revenues in fiscal year 2023 has deteriorated.2023 revenue forecast decreased from US$15.3m to US$12.4m.Forecast losses increased from -US$0.037 to -US$0.039 per share.Pharmaceuticals industry in the United Kingdom expected to see average net income growth of 37% next year.Consensus price target down from UK£0.15 to UK£0.02.Share price fell 3.7% to UK£0.014 over the past week.
Posted at 04/4/2024 18:19 by bolitix
Now i lost lots to these clowns so have now written that loss off. I did say this CEO would drag this share price near a penny some time ago. Now the worst could well be on the cards if they do a share exchange for the new company on a 1:10, 1:100 or even 1:1000 ratio to hype the price up on a Par so if 1:1000 the share price per share will be increased by a factor of 1000 to compensate but that will immediately drop lower. Hence, stay away from this company until it changes this CEO and its mindset.
Posted at 06/3/2024 14:56 by sam_
From another STX chat board:

“ we have several major shareholders, each holding less than 5% of the company's shares. This percentage serves as the requisite threshold for UK companies to inform the market of any changes in their holdings through a TR1 notification.

Jupiter Asset Management Ltd 4.364 %

Premier Fund Managers Ltd. 3.836 %

LGT Capital Partners AG (Investment Management) 3.669 %

KW Investment Management Ltd. 2.641 %

Jarvis Investment Management Ltd. 1.680 %

Given the substantial number of shares traded at the end of last month, I am inclined to believe that at least two major shareholders have offloaded their shares to the market and cashed out.

Regardless, the past is behind us, and we've observed a nice buying momentum gaining traction since the start of this week. I can see the share price smoothly rise back to the 4s from its current level. The technical chart is currently indicating a significant oversold condition on both the weekly and daily charts, making it an appealing prospect for chart and momentum traders as well.”
Posted at 27/2/2024 15:05 by bolitix
I said a couple of months ago this CEO will take this below 1p share price Even with a 200% sales gain over 2023 he has managed to take the share price down 25 fold to date. VTRS share price is about 13p and i dont know AOPs but which of these who take over we cant expect the share price to ever top theirs. Now i am not gloating here as i have lost lots on STX!
Posted at 23/2/2024 15:38 by base7
Greg talks a great story but has delivered an almost 100% write down in our share price since he took control.Our share price was recovering nicely at 12/13p until the disastrous 8p raise accompanied by disgraceful & obvious insider trading.AS ever, The Regulator did nothing & those shorting got away with it again.This weeks debacle of over stated prescription targets was another disgrace & either Greg of the CFO should have had an eye or two on that ball-resulting in cashflow break even being pushed back another 6-12 months & Greg & Santosh saying with confidence that we have sufficient cash to achieve that target must be taken with a pinch of salt or our share price would have recovered to the heady heights of 5p.
Greg has been in situ for long enough to sort out Norgine but they continue plodding along doing very little with their rights to sell our products in a market of 500m potential patients - surely we should potentially generate more revenue from Europe than US.
The only near term prospective good news is from Korea & Canada where we should soon be generating revenue - although that too is already several months behind schedule.
The only other action Greg & Santosh could now take to give The Market a sign of their confidence is to invest a relatively small amount of their large packages on a substantial number of share + take some of their remuneration in shares.If I was running a company which I had total belief in I would want as many shares as possible-especially with our share price at a 60%+ discount to the 8p raise .
Rant over - fine weekend to you all !
Posted at 06/12/2023 10:00 by cyberbub
I would have thought that AOP's average must be around 10p? If so, they won't sell out for less than 30p IMO. Who knows, if we see STX still making solid progress in the next update in January (especially if the GTN is increasingly rapidly) then the share price could easily jump to 15p-20p, and then is the moment for a bigger fish to pounce on us IMO, and offer 30p. Of course the share price could hit 40-50p in a couple of years time if all goes well, but I think a lot of shareholders (including me) would be happy to have a bird in the hand...
Shield Therapeutics share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock